Form 4: Sensei Biotherapeutics Director Bob Holmen Acquires 19,000 Stock Options

Director Bob Holmen of Sensei Biotherapeutics acquired 19,000 stock options at an exercise price of $0.709 on June 11, 2024.

Summary

• On June 11, 2024, Bob Holmen, a director of Sensei Biotherapeutics, acquired 19,000 stock options.
• The exercise price for these options is $0.709 per share.
• The options vest in 12 equal monthly installments over a year, fully vesting by June 11, 2025, contingent on continuous service.
• Full vesting will occur at the company's next annual stockholder meeting if the director remains in continuous service.
• Following the transaction, Holmen directly owns 19,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their confidence in the company's future.

Stakeholder Impact

• The transaction could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Sensei Biotherapeutics, SNSE, director, beneficial ownership, insider trading